RESULTS: A total of 1858 women (56% Jewish) had complete data for present analyses. Overall 83 women (4.5%) screened positive for mild PPD risk (EPDS 8) and 37 women (2.0%) screened positive for moderate PPD risk (EPDS 10). Logistic regression results showed that Cesarean delivery was significantly associated with mild PPD risk (OR¼3.04, 95% CI 2.00e4.60), which remained significant after adjusting for age and religion (OR 1.75, 95% CI 1.207e2.87, p¼0.03). CONCLUSION: Delivering by Cesarean section may be an independent risk factor for mild PPD symptoms in the immediate postpartum period. This cohort had low rates of PPD risk compared to epidemiological rates (10%), particularly in the Jewish women. Ethnic, racial and religious minorities encounter more stigma and may not readily report symptoms, therefore, cut-points are often lowered from the standard EPDS 10. Indeed, in our sample CS was significantly associated with EPDS 10 in the univariate model. Mild PPD risk in the immediate post partum period is also predictive of subsequent development of PPD. Obstetric providers may consider immediate PPD screening, education, and referral to treatment for patients, particularly for those who deliver via Cesarean section.
OBJECTIVE: Both trauma and pregnancy are risk factors for coagulation disorders, including venous thromboembolism (VTE) and disseminated intravascular coagulation (DIC), yet the association between trauma in pregnancy and coagulopathy has not been well described. To characterize the interplay between the two coagulopathic states, we sought to assess the prevalence of coagulation disorders in pregnant patients with and without trauma. STUDY DESIGN: We performed a retrospective cohort study of California Birth Registry data from 2007 to 2011. ICD-9 diagnosis and procedure codes were used to categorize patients into trauma and non-trauma cohorts, and to assess the prevalence of coagulation disorders. Chi-square tests were used to characterize maternal demographics and perform univariate analyses, and logistic regression was used to control for potential confounders. RESULTS: Of 2,406,605 singleton non-anomalous pregnancies, 1,262 (0.05%) experienced trauma prior to delivery. Groups were similar with regards to pre-pregnancy BMI (Table 1) . Smoking was more common in the trauma versus the non-trauma group, though the effect size was small (5.0% vs 3.3%, respectively; p<0.001). Placental abruption and preeclampsia were more common in women who experienced trauma (3.8% vs 0.81%, p<0.001, and 7.3% vs 4.1%, p<0.001, respectively). The prevalence of VTE did not vary between groups. Trauma was associated with increased odds of composite coagulation disorders even after controlling for maternal factors (aOR 8.9, p<0.01) ( Table 2 ). The odds of DIC was higher in the trauma group after controlling for important maternal characteristics; this effect was seen even after excluding women with placental abruption (aOR 13.5, p<0.001). CONCLUSION: Among pregnant patients, trauma is not associated with increased prevalence of VTE, but does increase the odds of coagulation disorders generally. This effect may be driven by a greater than 13-fold increase in the odds of developing DIC, which was seen even after excluding women with placental abruption, an important cause of DIC in pregnancy. Future research is needed to evaluate the efficacy and safety of interventions for DIC in pregnant and postpartum trauma patients.
OBJECTIVE:
We previously demonstrated that, in an effort to reduce the rate of stillbirth in this high-risk population, considering class III obesity an indication for delivery at 39 weeks did not affect overall rates of cesarean delivery or maternal or neonatal morbidity, despite an increase in the rate of labor induction from 41.6% to 49.2%. The current analysis evaluated time spent on the labor and delivery unit (L&D), and maternal and neonatal length of hospital stay. STUDY DESIGN: A secondary analysis was conducted using data from a before-and-after cohort study of women with BMI 40 delivering at our institution at term during the pre-(May 2012-April 2014) and post-policy (September 2014-August 2016) periods. Multifetal gestations and known fetal anomalies were excluded. The primary outcome was hours on L&D. Secondary outcomes were maternal and neonatal lengths of hospital stay. Outcome distributions were compared using Wilcoxon rank sum tests. Ratios of geometric mean time spent on L&D were estimated for the post-policy patients compared to pre-policy patients using linear regression models with log transformation of the outcome. For length of stay comparisons, zero-truncated negative binomial models were used to estimate rate ratios and 95% confidence intervals (CI). Models were adjusted for age, race/ethnicity, parity, BMI, prior cesarean, induction of labor, and payor. RESULTS: 1210 patients were included, 580 pre-and 630 post-policy. Median (25 th -75 th centile) hours on L&D were 18.4 (10.3-28.1) and 16.9 (9.9-26.5) in the post-and pre-policy groups, respectively (p¼0.22). The ratio of geometric mean (GM) hours for postcompared to pre-policy groups was close to unity in crude (GM ratio¼1.04, 95% CI 0.97, 1.13) and adjusted (GM ratio¼1.02, 95% CI 0.97, 1.09) models. Post-policy maternal length of stay did not differ from pre-policy values (adjusted rate ratio¼0.95, 95% CI 0.88-1.03). Neonatal length of stay was also similar between groups (adjusted rate ratio¼1.12, 95% CI 1.00-1.26).
Poster Session III RESULTS: Fetal growth parameters for the entire cohort were overall normal, with normal third trimester estimated fetal weight percentiles and birth weight percentiles (45+/-26% and 54.6+/-25.9% respectively), with only 3.2% of the population meeting criteria for growth restriction. The average gestational age at delivery was 38.1 weeks. When stratified by maternal cardiac risk there was no association with CARPREG scores (greater than 1) or WHO risk scores (greater than 2) and fetal growth patterns. Pregnancies were also stratified by ejection fractions <35% and >35%, which did not show significance. This was not altered when stratifying patients into history of peripartum cardiomyopathy or hereditary cardiomyopathy. There were no other parameters that were associated with fetal growth restriction in this cohort. CONCLUSION: Cardiac output and function are believed to have an impact on fetal growth. Optimal strategies on antenatal surveillance, growth ultrasounds, and management have not been established. This study did not find an association with cardiomyopathy and growth restriction. Incidentally, fewer growth restricted infants were found than would be expected in the general population, however, this study is limited by the sample size. Future studies are needed to further elucidate the association of cardiomyopathy and heart function on fetal growth to provide evidence-based guidance on antenatal surveillance and counseling in this high risk population. OBJECTIVE: Chemotherapy exposure during pregnancy has been variably associated with adverse outcomes, including growth restriction. We sought to confirm this association and evaluate impact by the type, gestational age (GA) at initiation, and duration of chemotherapy. We also assessed whether growth restriction is correlated with placental pathology. STUDY DESIGN: Our cohort included women diagnosed with breast cancer in pregnancy (BCP) between 1996-2017 at three academic centers. Univariate and regression analyses were used to analyze oncologic treatment and obstetric outcomes. Primary outcomes were neonatal birthweight, controlled for GA at delivery, and small for gestational age infant (SGA). Preplanned sensitivity analyses were performed. RESULTS: The cohort included 110 women with BCP who had a singleton live birth; 64 (58.2%) had complete obstetric and 45 (40.9%) placental data available. Sixty-three (57.8%) received chemotherapy in pregnancy, consisting of doxorubicin and cyclophosphamide (AC) and taxanes (T) (Figure 1) . Median GA at chemotherapy initiation was 22 weeks. There was no difference in GA at delivery between those who did and did not receive chemotherapy (36.9 vs 37.3 weeks, p¼0.34). Chemotherapy was associated with lower birthweight (2740g vs 3022g, p¼0.037) but not increased SGA (21% vs 10%, p¼0.49). Taxane exposure specifically was associated with decreased birthweight (p¼0.04) but also longer chemotherapy duration (9.8 vs 17.4 wks, p<0.001). Earlier GA at chemotherapy initiation was associated with increased SGA (p¼0.027), which persisted when controlling for length of exposure (p¼0.022). Placental weight was lower in the group exposed to chemotherapy (390g vs 480g, p¼0.046), and smaller placentas were associated with SGA (p<0.01); however, there was no difference in the rate of placental infarct, hematoma, or chorioamnionitis (37.5% vs 42.1%, p¼1.0). Composite obstetrical outcomes (p¼0.53) and neonatal outcomes (p¼0.12) did not differ by chemotherapy exposure (Table 1) . CONCLUSION: Chemotherapy for BCP was associated with decreased neonatal birthweight and placental weight, but similar rates of SGA and placental lesions. Lower birthweights were associated with earlier initiation of chemotherapy and taxane exposure, but the latter is confounded by longer duration of chemotherapy. This raises further questions about mediators of growth restriction in women exposed to chemotherapy in BCP.
